Skip to main content
. Author manuscript; available in PMC: 2013 Jun 13.
Published in final edited form as: Oncogene. 2012 Feb 20;31(50):5172–5179. doi: 10.1038/onc.2012.9

Figure 4.

Figure 4

(a) The relative level of AID mRNA in MEFs treated with 5-Aza-dC (1 μM). (b) The effect of AID down-regulation on mutagenic properties of 5-Aza-dC (c) The effect of PARP-1 inhibitor olaparib on mutagenic properties of 5-Aza-dC. (d) The effect of PARP-1 inhibitor olaparib on cytotoxic/cytostatic properties of 5-Aza-dC. Data shown as average ±SD; asterisk (*) designates statistically significant difference with corresponding control (* - p<0.05; ** - p<0.01; *** - p<0.001).